mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

Nephrol Dial Transplant. 2022 Mar 25;37(4):799-803. doi: 10.1093/ndt/gfab352.

Veerle P W M Wijtvliet^{1

2}, Kevin K Ariën^{3

4}, Steven Abrams^{5

6}, Marie M Couttenye^{1

2}, Fabienne Mestrez⁷, Joachim Mariën^{3

8}, Benedicte Y De Winter¹, Pierre Van Damme⁹, Lissa Pipeleers¹⁰, Karl Martin Wissing¹⁰, Daniel Abramowicz^{1

2}, Kristien J Ledeganck¹

¹ Laboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium.
² Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium.
³ Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
⁴ Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
⁵ Department of Epidemiology and Social Medicine, Global Health Institute, University of Antwerp, Antwerp, Belgium.
⁶ I-BioStat, Data Science Institute, Hasselt University, Diepenbeek, Belgium.
⁷ Department of Nephrology-Dialysis, University Hospital (CHU) Ambroise Paré, Mons, Belgium.
⁸ Evolutionary Ecology Group, Department of Biology, University of Antwerp, Antwerp, Belgium.
⁹ Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
¹⁰ Department of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

No abstract available

MeSH terms